Actively building life science companies

5AM Ventures is a leading venture capital firm focused on building next-generation life science companies capable of delivering outstanding returns to our investors.

Scroll to experience 5AM Ventures

Supporting companies that are working to solve important healthcare needs via cutting-edge breakthroughs in medicine and science.

Read Me

Bird Rock Bio Announces Successful Completion of Phase 1B Safety Study and Readiness for Phase 2B Study of Nimacimab in Patients with Diabetic Kidney Disease
Read Me

IDEAYA Announces First Patient Dosing of IDE196 for Solid Tumors Outside of Uveal Melanoma and a Collaboration with Foundation Medicine in Support of its Tumor-Agnostic GNAQ/11 Basket Trial
Read Me

Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Read Me

Audentes Therapeutics Presents New Positive Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society
Read Me

Cabaletta Bio Announces Presentation of Preclinical Data Showing Specific CAAR T Activity Against Anti-MuSK Expressing B Cells

Pushing the healthcare industry forward

$ 0 B

UNDER MANAGEMENT

We’re a life science venture capital firm founded in 2002 and currently investing $350M from 5AM Ventures VI and $147M from 5AM Opportunities I.
0

PORTFOLIO COMPANIES

Our focus is biopharmaceuticals, drug delivery technologies and life science instruments.
0

ONGOING CLINICAL TRIALS

Our portfolio companies currently have over 18,000 patients enrolled across 750 test sites in ongoing clinical trials.

San Francisco, CA

Boston, MA